Want to join the conversation?
David Risinger of Morgan Stanley asks for an update on Botox and its opportunities. $AGN said it is only halfway through the life and growth of Botox, both aesthetically and therapeutically. The company sees this as a pipeline and a product which will be a key growth driver for $AGN for the next decade or more.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.